{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:39Z","timestamp":1793196579907,"version":"4.5.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004470","name":"Daewoong Pharmaceutical Company","doi-asserted-by":"publisher","award":["9-2023-0064"],"award-info":[{"award-number":["9-2023-0064"]}],"id":[{"id":"10.13039\/501100004470","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2024-0188"],"award-info":[{"award-number":["6-2024-0188"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proton pump inhibitors are standard for preventing upper gastrointestinal (UGI) complications in patients receiving antithrombotic therapy, but their limitations highlight the need for alternatives. Potassium-competitive acid blockers (P-CABs), such as fexuprazan, are emerging substitutes, yet evidence supporting their protective role in this setting remains limited. This study aimed to evaluate the effect of fexuprazan in patients with acute ischemic stroke (AIS) and gastroesophageal reflux disease (GERD) receiving antithrombotic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, single-center, single-arm study included consecutive patients with AIS and GERD who were receiving antithrombotic therapy and treated with fexuprazan between June 2023 and March 2025. At the study hospital, all admitted AIS patients were systematically screened for GERD using the Gastroesophageal Reflux Disease Questionnaire (GerdQ), with a score \u22658 indicating GERD. The primary outcome was the change in GerdQ score from baseline to 12 weeks after the index AIS. Safety outcomes included recurrent stroke or serious adverse events within 12 weeks. The secondary efficacy outcome was the occurrence of a composite of UGI clinical events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 623 patients with AIS screened during the study period, 18 patients with GERD receiving antithrombotic therapy and treated with fexuprazan were enrolled and followed for 12 weeks. The mean age was 65.6 years, and 9 patients (50.0%) were male. The mean GerdQ score significantly improved from 8.8\u2009\u00b1\u20092.3 at baseline to 6.6\u2009\u00b1\u20091.7 at 12 weeks (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003). A normal GerdQ score (&lt;8) was achieved in 88.9% of the patients. One patient (5.6%) experienced a UGI clinical event and one had a recurrent transient ischemic attack.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This preliminary prospective single-arm study using a structured symptom-based assessment suggests that fexuprazan may be associated with symptom relief in patients with AIS and GERD receiving antithrombotic therapy. However, due to the small sample size and lack of a control group, these findings should be interpreted as hypothesis-generating and warrant further confirmation in larger, controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0346145","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:52:49Z","timestamp":1775238769000},"page":"e0346145","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fexuprazan for upper gastrointestinal protection in patients with ischemic stroke and gastroesophageal reflux disease (GERD) receiving antithrombotic therapy: A preliminary prospective single-arm observational Study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6582-0953","authenticated-orcid":true,"given":"Minyoul","family":"Baik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong\u00a0A.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonsang","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"34","key":"pone.0346145.ref001","article-title":"Contemporary Statistics of Acute Ischemic Stroke and Transient Ischemic Attack in 2021: Insights From the CRCS-K-NIH Registry","volume":"39","author":"DY Kim","year":"2024","journal-title":"J Korean Med Sci"},{"issue":"7","key":"pone.0346145.ref002","doi-asserted-by":"crossref","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association","volume":"52","author":"DO Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"18","key":"pone.0346145.ref003","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use","volume":"118","author":"Writing Committee M","year":"2008","journal-title":"Circulation"},{"key":"pone.0346145.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.11.014","article-title":"Gastroprotection in patients on antiplatelet and\/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)","volume":"85","author":"MG Abrignani","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"4","key":"pone.0346145.ref005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5056\/jnm21077","article-title":"2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease","volume":"27","author":"H-K Jung","year":"2021","journal-title":"J Neurogastroenterol Motil"},{"issue":"14","key":"pone.0346145.ref006","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"42","author":"J-P Collet","year":"2021","journal-title":"European Heart Journal"},{"key":"pone.0346145.ref007","doi-asserted-by":"crossref","first-page":"17562848221122623","DOI":"10.1177\/17562848221122623","article-title":"The role of vonoprazan in patients with erosive esophagitis","volume":"15","author":"M Zhang","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"issue":"7","key":"pone.0346145.ref008","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"H Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"pone.0346145.ref009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?","volume":"9","author":"P Rawla","year":"2018","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"12","key":"pone.0346145.ref010","first-page":"693","article-title":"Potassium-competitive acid blockers: present and potential utility in the armamentarium for acid peptic disorders","volume":"18","author":"N Wong","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"44","key":"pone.0346145.ref011","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.3748\/wjg.v28.i44.6294","article-title":"Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis","volume":"28","author":"KN Lee","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"4","key":"pone.0346145.ref012","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jgh.16471","article-title":"The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study","volume":"39","author":"Q Zhuang","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"pone.0346145.ref013","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2050640613485238","article-title":"Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan","volume":"1","author":"H Suzuki","year":"2013","journal-title":"United European Gastroenterol J"},{"issue":"4","key":"pone.0346145.ref014","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jgh.12125","article-title":"Gastroesophageal Reflux Disease Questionnaire (GerdQ) in real-world practice: a national multicenter survey on 8065 patients","volume":"28","author":"Y Bai","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"pone.0346145.ref015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5056\/jnm18133","article-title":"Validation of the Korean Version of the Gastroesophageal Reflux Disease Questionnaire for the Diagnosis of Gastroesophageal Reflux Disease","volume":"25","author":"EJ Gong","year":"2019","journal-title":"J Neurogastroenterol Motil"},{"issue":"20","key":"pone.0346145.ref016","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"DL Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"pone.0346145.ref017","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs","volume":"4","author":"D Lakens","year":"2013","journal-title":"Front Psychol"},{"issue":"3","key":"pone.0346145.ref018","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"24","key":"pone.0346145.ref019","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","article-title":"ACCF\/ACG\/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF\/ACG\/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use","volume":"122","author":"NS Abraham","year":"2010","journal-title":"Circulation"},{"issue":"10","key":"pone.0346145.ref020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4070\/kcj.2020.0196","article-title":"Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction","volume":"50","author":"HK Kim","year":"2020","journal-title":"Korean Circ J"},{"key":"pone.0346145.ref021","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","author":"RA Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"pone.0346145.ref022","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s44197-024-00267-9","article-title":"Proton Pump Inhibitor for Gastrointestinal Bleeding in Patients with Myocardial Infarction on Dual-Antiplatelet Therapy: A Nationwide Cohort Study","volume":"14","author":"M Baik","year":"2024","journal-title":"J Epidemiol Glob Health"},{"issue":"6","key":"pone.0346145.ref023","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","article-title":"Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study","volume":"67","author":"T Kawai","year":"2018","journal-title":"Gut"},{"key":"pone.0346145.ref024","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jgh.16989","article-title":"Effect of Potassium-Competitive Acid Blockers on Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study","volume":"40","author":"M Baik","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0346145.ref025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ahj.2025.04.001","article-title":"Potassium-competitive acid blocker vs proton-pump inhibitor in patients receiving antithrombotic therapy who are at high risk for gastrointestinal bleeding: Rationale and design of the randomized PROTECT- HBR trial","volume":"287","author":"J Lee","year":"2025","journal-title":"Am Heart J"},{"key":"pone.0346145.ref026","article-title":"The six-question Gastroesophageal Reflux Disease Questionnaire (GerdQ) cannot accurately quantify reflux and reflux-associated symptoms frequency","volume":"10","author":"TJ Hurr","year":"2022","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"4","key":"pone.0346145.ref027","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000350438","article-title":"Antiplatelet drugs are a risk factor for esophageal mucosal injury","volume":"87","author":"M Sugimoto","year":"2013","journal-title":"Digestion"},{"key":"pone.0346145.ref028","doi-asserted-by":"crossref","first-page":"1295051","DOI":"10.3389\/fneur.2023.1295051","article-title":"Association between gastroesophageal reflux disease and stroke: a bidirectional Mendelian randomization study","volume":"14","author":"D Meng","year":"2024","journal-title":"Front Neurol"},{"issue":"5","key":"pone.0346145.ref029","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.12.001","article-title":"Patients with Cerebral Stroke Have an Increased Risk of Gastroesophageal Reflux Disease: A Population-Based Cohort Study","volume":"27","author":"C-S Chang","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"2","key":"pone.0346145.ref030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000323927","article-title":"Effects of environment and lifestyle on gastroesophageal reflux disease","volume":"29","author":"A Sonnenberg","year":"2011","journal-title":"Dig Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:52:53Z","timestamp":1775238773000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346145"}},"subtitle":[],"editor":[{"given":"Devesh U","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0346145","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}